Atovaquone versus trimethoprim-sulfamethoxazole as Pneumocystis jirovecii pneumonia prophylaxis following renal transplantation

Clinical Transplantation

Volumn 26, Issue 3, 2012, Pages

  Gabardi, Steven ^a,b   Millen, Peter ^a   Hurwitz, Shelley ^a,b   Martin, Spencer ^c   Roberts, Keri ^a   Chandraker, Anil ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Infectious disease; Pneumocystis jirovecii; Renal transplantation

Indexed keywords

ATOVAQUONE; BASILIXIMAB; CIPROFLOXACIN; COTRIMOXAZOLE; CREATININE; LEVOFLOXACIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POLYSTYRENESULFONATE SODIUM; POTASSIUM; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CLINICAL EVALUATION; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPIDEMIOLOGY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERKALEMIA; INCIDENCE; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; VIREMIA;

ANTI-INFECTIVE AGENTS; ATOVAQUONE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84862242419     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2012.01624.x     Document Type: Article

References (29)

1. Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for pneumocystis from humans. Emerg Infect Dis 2002: 8: 891.
2. Kovacs JA, Gill VJ, Meshnick S, Masur H. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA 2001: 286: 2450.
3. Fishman JA. Prevention of infection due to Pneumocystis carinii. Antimicrob Agents Chemother 1998: 42: 995.
4. Radisic M, Lattes R, Chapman JF et al. Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: a case-control study. Transpl Infect Dis 2003: 5: 84.
5. Gordon SM, LaRosa SP, Kalmadi S et al. Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? Clin Infect Dis 1999: 28: 240.
6. Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004: 17: 770, table of contents.
7. Dummer JS, Montero CG, Griffith BP, Hardesty RL, Paradis IL, Ho M. Infections in heart-lung transplant recipients. Transplantation 1986: 41: 725.
8. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996: 71: 5.
9. Hughes MA, Parisi M, Grossman S, Kleinberg L. Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection. Int J Radiat Oncol Biol Phys 2005: 62: 1423.
10. Rice WR, Singleton FM, Linke MJ, Walzer PD. Regulation of surfactant phosphatidylcholine secretion from alveolar type II cells during Pneumocystis carinii pneumonia in the rat. J Clin Invest 1993: 92: 2778.
11. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007: 357: 2601.
12. Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006: 43: 16.
13. Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis 2001: 33: 1397.
14. Martin SI, Fishman JA. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant 2009: 9(Suppl 4): S227.
15. Dapsone [package insert]. Princeton, NJ: Jacobus Pharmaceuticals; Revised August 2009. In; 2009.
16. Lee I, Barton TD, Goral S et al. Complications related to dapsone use for Pneumocystis jirovecii pneumonia prophylaxis in solid organ transplant recipients. Am J Transplant 2005: 5: 2791.
17. Coleman MD. Dapsone toxicity: some current perspectives. Gen Pharmacol 1995: 26: 1461.
18. Jollow DJ, Bradshaw TP, McMillan DC. Dapsone-induced hemolytic anemia. Drug Metab Rev 1995: 27: 107.
19. Plotkin JS, Buell JF, Njoku MJ et al. Methemoglobinemia associated with dapsone treatment in solid organ transplant recipients: a two-case report and review. Liver Transpl Surg 1997: 3: 149.
20. Zosel A, Rychter K, Leikin JB. Dapsone-induced methemoglobinemia: case report and literature review. Am J Ther 2007: 14: 585.
21. NebuPent [package insert]. Schaumburg, IL: APP Pharmaceuticals; Revised February 2008. In; 2008.
22. Mepron [package insert]. Research Triangle Park, NC: GlaxoSmithKline; Revised May 2008. In; 2008.
23. Colby C, McAfee S, Sackstein R, Finkelstein D, Fishman J, Spitzer T. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999: 24: 897.
24. El-Sadr WM, Murphy RL, Yurik TM et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. N Engl J Med 1998: 339: 1889.
25. Ali SH, Chandraker A, DeCaprio JA. Inhibition of Simian virus 40 large T antigen helicase activity by fluoroquinolones. Antivir Ther 2007: 12: 1.
26. Gabardi S, Waikar SS, Martin S et al. Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation. Clin J Am Soc Nephrol 2010: 5: 1298.
27. Meyers B, Borrego F, Papanicolaou G. Pneumocystis carinii pneumonia prophylaxis with atovaquone in trimethoprim-sulfamethoxazole-intolerant orthotopic liver transplant patients: a preliminary study. Liver Transpl 2001: 7: 750.
28. Rodriguez M, Sifri CD, Fishman JA. Failure of low-dose atovaquone prophylaxis against Pneumocystis jiroveci infection in transplant recipients. Clin Infect Dis 2004: 38: e76.
29. 2010 Red Book. Pharmacy's Fundamental Reference. Montvale, NJ: Thomson Healthcare, Inc., 2010.